Zidong Zhang

Dr. Zidong Zhang

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2018 in Development
Verified
Journal Article
Open access
PDF file
RMRajasree Menon
Rajasree Menon
EOEdgar A. Otto
Edgar A. Otto
AKAustin Kokoruda
Austin Kokoruda
JZJian Zhou
Jian Zhou
ZZZidong Zhang
Zidong Zhang
CCCristina Cebrián
Cristina Cebrián
The mammalian kidney develops through reciprocal interactions between the ureteric bud and the metanephric mesenchyme to give rise to the entire collecting system and the nephrons. Most of our knowledge of the developmental regulators driving this process arises from the study of gene expression and functional genetics in mice and other animal models. In order to shed light on human kidney development, we have used single-cell transcriptomics to characterize gene expression in different cell populations, and to study individual cell dynamics and lineage trajectories during development. Single-cell transcriptome analyses of 6414 cells from five individual specimens identified 11 initial clusters of specific renal cell types as defined by their gene expression profile. Further subclustering identifies progenitors, and mature and intermediate stages of differentiation for several renal lineages. Other lineages identified include mesangium, stroma, endothelial and immune cells. Novel markers for these cell types were revealed in the analysis, as were components of key signaling pathways driving renal development in animal models. Altogether, we provide a comprehensive and dynamic gene expression profile of the developing human kidney at the single-cell level.

24 February 2017 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
HRHenry B. Randall
Henry B. Randall
TATarek Alhamad
Tarek Alhamad
MSMark A. Schnitzler
Mark A. Schnitzler
ZZZidong Zhang
Zidong Zhang
SFSophia Ford‐Glanton
Sophia Ford‐Glanton
KLKrista L Lentine
Krista L Lentine

26 February 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KLKrista L Lentine
Krista L Lentine
ANAbhijit S. Naik
Abhijit S. Naik
MSMark A. Schnitzler
Mark A. Schnitzler
HRHenry Randall
Henry Randall
JWJason R. Wellen
Jason R. Wellen
DADavid A. Axelrod
David A. Axelrod
Use of procurement biopsies in deceased donor kidney acceptance is controversial. We analyzed Scientific Registry of Transplant Recipients data (n = 59,328 allografts, 2014‐2018) to describe biopsy practices across US organ procurement organizations (OPOs) and examine relationships with discards, using hierarchical modeling to account for OPO and donor factors. Median odds ratios (MORs) provide medians of the odds that allografts with identical reported traits would be biopsied or discarded from two randomly drawn OPOs. Biopsies were obtained for 52.7% of kidneys. Biopsy use rose in a graded manner with kidney donor profile index (KDPI). Biopsy rates differed significantly among OPOs (22.8% to 77.5%), even after adjustment for KDPI and other donor factors. Discard rates also varied from 6.6% to 32.1% across OPOs. After adjustment for donor factors and OPO, biopsy was associated with more than 3 times the likelihood of discard (adjusted odds ratio (95%LCLaOR95%UCL), 3.293.513.76). This association was most pronounced for low‐risk (KDPI 85 (aOR, 0.881.151.51). Adjusted MORs for kidney discard and biopsy were greatest for low‐risk kidneys. Reducing the rate of unnecessary biopsy and improving the accuracy of pathologic findings in higher‐KDPI organs may help reduce graft discard rates.

6 August 2013 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Open access
PDF file
LLLifang Li
Lifang Li
LLLanfang Li
Lanfang Li
FXFeng Xie
Feng Xie
ZZZidong Zhang
Zidong Zhang
YGYu Guo
Yu Guo
JLJian Li
Jian Li
The apelin/apelin receptor (APJ, apelin–angiotensin receptor-like 1) system is a newly deorphanized G protein-coupled receptor system. Both apelin and APJ that are important regulatory factors are expressed in the cardiovascular system. Our previous studies demonstrated that apelin-13 significantly stimulated vascular smooth muscle cell (VSMC) proliferation. In this paper, our data suggested that the Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced VSMC proliferation by promoting the expression of Cyclin D1. Results indicated that apelin-13 stimulates the proliferation of VSMC and the expression of Jagged-1 and Notch3 in concentration- and time-dependent manners. The increased expression of Jagged-1 and Notch3 induced by apelin-13 could be abolished by extracellular signal-regulated protein kinase (ERK) blockade. PD98059 (ERK inhibitor) can inhibit the activation of Jagged-1/Notch3 induced by apelin-13. Down-regulation of Notch3 using small interfering RNA inhibits the expression of Cyclin D1 and prevents apelin-13-induced VSMC proliferation. In conclusion, Jagged-1/Notch3 signaling transduction pathway is involved in VSMC proliferation induced by apelin-13.

7 October 2017 in Transplant International
Verified
Journal Article
Open access
PDF file
VDVikas R. Dharnidharka
Vikas R. Dharnidharka
ANAbhijit S. Naik
Abhijit S. Naik
DADavid A. Axelrod
David A. Axelrod
MSMark A. Schnitzler
Mark A. Schnitzler
ZZZidong Zhang
Zidong Zhang
KLKrista L Lentine
Krista L Lentine
To assess factors that influence the choice of induction regimen in contemporary kidney transplantation, we examined center‐identified, national transplant registry data for 166 776 US recipients (2005–2014). Bilevel hierarchical models were constructed, wherein use of each regimen was compared pairwise with use of interleukin‐2 receptor blocking antibodies (IL2rAb). Overall, 82% of patients received induction, including thymoglobulin (TMG, 46%), IL2rAb (22%), alemtuzumab (ALEM, 13%), and other agents (1%). However, proportions of patients receiving induction varied widely across centers (0–100%). Recipients of living donor transplants and self‐pay patients were less likely to receive induction treatment. Clinical factors associated with use of TMG or ALEM (vs. IL2rAb) included age, black race, sensitization, retransplant status, nonstandard deceased donor, and delayed graft function. However, these characteristics explained only 10–33% of observed variation. Based on intraclass correlation analysis, “center effect” explained most of the variation in TMG (58%), ALEM (66%), other (51%), and no induction (58%) use. Median odds ratios generated from case‐factor adjusted models (7.66–11.19) also supported large differences in the likelihood of induction choices between centers. The wide variation in induction therapy choice across US transplant centers is not dominantly explained by differences in patient or donor characteristics; rather, it reflects center choice and practice.

2 March 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KLKrista L Lentine
Krista L Lentine
NLN. N. Lam
N. N. Lam
ANA. S. Naik
A. S. Naik
DAD. A. Axelrod
D. A. Axelrod
ZZZidong Zhang
Zidong Zhang
MSM. A. Schnitzler
M. A. Schnitzler
Evolving literature suggests that the epidemic of prescription opioid use affects the transplant population. We examined a novel database wherein national U.S. transplant registry records were linked to a large pharmaceutical claims warehouse (2007-2015) to characterize prescription opioid use before and after kidney transplant, and associations (adjusted hazard ratio, 95% LCLaHR95% UCL) with death and graft loss. Among 75 430 eligible patients, 43.1% filled opioids in the year before transplant. Use was more common among recipients who were women, white, unemployed, publicly insured, and with longer pretransplant dialysis. Of those with the highest level of pretransplant opioid use, 60% continued high-level use posttransplant. Pretransplant opioid use had graded associations with one-year posttransplant outcomes; the highest-level use predicted 46% increased risk of death (aHR 1.281.461.66) and 28% increased risk of all-cause graft failure (aHR 1.171.281.41). Effects of high-level opioid use in the first year after transplant were stronger, predicting twice the risk of death (aHR 1.932.242.60) and 68% higher all-cause graft failure risk (aHR 1.501.681.89) over the subsequent year; increased risk persisted over five years. While associations may, in part, reflect underlying conditions or behaviors, opioid use history is relevant in assessing and providing care to transplant candidates and recipients.